Mortgage Rates Decline Across the Board on May 22 2026 30Year Fixed Drops to 646 Microsofts Largest India Data Center on Track for Mid2026 Opening US April Payrolls Surge Above Expectations Yet Underlying Concerns Emerge US Government Stake Speculation IonQ Micron and Anduril Emerge as Potential Targets After Quantum Investments Prediction Markets Highlight IonQ Micron and Anduril as Potential Next Targets for US Government Stake Huawei Unveils New Chip Design Method Intensifying Rivalry with Nvidia and Apple JTAI Q1 2026 Earnings EPS Falls Short of Estimates Stock Rises 217 ANTA Q1 2026 Earnings Significant EPS Miss Triggers Stock Decline MUR Q1 2026 Earnings EPS Beat Drives Modest Stock Uptick Live Oak Bancshares Inc Q1 2026 Earnings EPS Surprises to the Upside Amid Market Caution Tecogen Inc TGEN Q1 2026 Earnings Narrower Loss Surprises Street as Stock Gains 415 Quantum Biopharma Ltd QNTM Q4 2025 Earnings Biotech Firm Reports Wider Loss Amid Lack of Revenue Visibility Scilex Holding Company Warrant SCLXW Slides 14 as Momentum Falters Near Support Vince Holding Corp VNCE Edges Higher as Shares Test Key Support Levels Clorox CLX Holds Steady Near 95 as Traders Eye Key Support and Resistance Levels HubSpot HUBS Edges Higher as Investors Eye Key Resistance Level Janus Henderson Group JHG Holds Steady Near 52 as Key Levels Loom Vickers Insider Picks for May 28 2026 Key Signals in Corporate Trading Activity Nomad Foods Q1 2026 Earnings EPS Surprises 214 Above Estimates Amid Weaker Stock Reaction Shopify SHOP Advances 184 as Bullish Momentum Builds Toward Key Resistance PLG Q4 2023 Earnings SmallerThanExpected Loss Outpaces Analyst Estimates Biglari Holdings Q1 2025 Earnings Strong EPS Performance Amid Limited Visibility DCTH Q1 2026 Earnings SmallerthanExpected Loss Despite No Reported Revenue Mirion Technologies Q1 2026 Earnings EPS Beats Estimates Stock Rises Over 4 BKD Q1 2026 Earnings EPS Misses Estimates as Occupancy Headwinds Persist Century Communities Q1 2026 Earnings Strong EPS Beat Amid Mixed Market Signals Ovid Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Supports Biotechs Cash Discipline